USD 0.18
(0.0%)
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2023 | -456.76 Thousand CAD | -657.22% |
2022 | -60.32 Thousand CAD | 8.04% |
2021 | -65.59 Thousand CAD | 1.16% |
2020 | -66.36 Thousand CAD | -29.87% |
2019 | -51.1 Thousand CAD | -83.77% |
2018 | -27.8 Thousand CAD | -632.56% |
2017 | -3796.00 CAD | -377.48% |
2016 | -795.00 CAD | 48.11% |
2015 | -1532.00 CAD | 0.0% |
2014 | - CAD | 0.0% |
2013 | - CAD | 0.0% |
2012 | - CAD | 0.0% |
2011 | - CAD | 0.0% |
2010 | - CAD | 0.0% |
2009 | - CAD | -100.0% |
2008 | 262.62 Thousand CAD | -6.12% |
2007 | 279.73 Thousand CAD | 7513.91% |
2006 | 3674.00 CAD | 0.0% |
2005 | - CAD | 0.0% |
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2024 Q1 | -185.86 Thousand CAD | 5.59% |
2024 Q2 | -183.81 Thousand CAD | 1.1% |
2024 Q3 | - CAD | 100.0% |
2023 FY | -456.76 Thousand CAD | -657.22% |
2023 Q3 | -182.27 Thousand CAD | -176.16% |
2023 Q2 | -66 Thousand CAD | -468.26% |
2023 Q4 | -196.87 Thousand CAD | -8.01% |
2023 Q1 | -11.61 Thousand CAD | 21.22% |
2022 Q3 | -14.74 Thousand CAD | -3.37% |
2022 Q1 | -16.57 Thousand CAD | -1.48% |
2022 Q4 | -14.74 Thousand CAD | 0.01% |
2022 Q2 | -14.26 Thousand CAD | 13.93% |
2022 FY | -60.32 Thousand CAD | 8.04% |
2021 FY | -65.59 Thousand CAD | 1.16% |
2021 Q1 | -16.53 Thousand CAD | 0.0% |
2021 Q2 | -16.09 Thousand CAD | 2.7% |
2021 Q3 | -16.63 Thousand CAD | -3.37% |
2021 Q4 | -16.33 Thousand CAD | 1.83% |
2020 Q2 | - CAD | 0.0% |
2020 Q4 | - CAD | 0.0% |
2020 FY | -66.36 Thousand CAD | -29.87% |
2020 Q1 | - CAD | 0.0% |
2020 Q3 | - CAD | 0.0% |
2019 Q1 | - CAD | 0.0% |
2019 Q2 | - CAD | 0.0% |
2019 Q4 | - CAD | 0.0% |
2019 FY | -51.1 Thousand CAD | -83.77% |
2019 Q3 | - CAD | 0.0% |
2018 FY | -27.8 Thousand CAD | -632.56% |
2018 Q4 | - CAD | 0.0% |
2018 Q3 | - CAD | 0.0% |
2018 Q2 | - CAD | 0.0% |
2018 Q1 | - CAD | 0.0% |
2017 Q3 | - CAD | 0.0% |
2017 FY | -3796.00 CAD | -377.48% |
2017 Q4 | - CAD | 0.0% |
2017 Q2 | - CAD | 0.0% |
2017 Q1 | - CAD | 0.0% |
2016 Q2 | - CAD | 0.0% |
2016 Q4 | - CAD | 0.0% |
2016 Q3 | - CAD | 0.0% |
2016 FY | -795.00 CAD | 48.11% |
2016 Q1 | - CAD | 0.0% |
2015 Q1 | - CAD | 0.0% |
2015 Q4 | - CAD | 0.0% |
2015 Q3 | - CAD | 0.0% |
2015 Q2 | - CAD | 0.0% |
2015 FY | -1532.00 CAD | 0.0% |
2014 Q4 | - CAD | 0.0% |
2014 Q1 | - CAD | 0.0% |
2014 Q2 | - CAD | 0.0% |
2014 Q3 | - CAD | 0.0% |
2014 FY | - CAD | 0.0% |
2013 FY | - CAD | 0.0% |
2013 Q3 | - CAD | 0.0% |
2013 Q2 | - CAD | 0.0% |
2013 Q1 | - CAD | 0.0% |
2013 Q4 | - CAD | 0.0% |
2012 Q3 | - CAD | 0.0% |
2012 Q4 | - CAD | 0.0% |
2012 FY | - CAD | 0.0% |
2012 Q1 | - CAD | 0.0% |
2012 Q2 | - CAD | 0.0% |
2011 Q4 | - CAD | 0.0% |
2011 Q2 | - CAD | 0.0% |
2011 Q3 | - CAD | 0.0% |
2011 FY | - CAD | 0.0% |
2011 Q1 | - CAD | 0.0% |
2010 Q1 | - CAD | 100.0% |
2010 FY | - CAD | 0.0% |
2010 Q3 | - CAD | 0.0% |
2010 Q4 | - CAD | 0.0% |
2010 Q2 | - CAD | 0.0% |
2009 FY | - CAD | -100.0% |
2009 Q2 | 1329.00 CAD | -78.35% |
2009 Q4 | -7960.00 CAD | -1714.6% |
2009 Q3 | 493.00 CAD | -62.9% |
2009 Q1 | 6138.00 CAD | -65.39% |
2008 Q2 | 74.41 Thousand CAD | -43.44% |
2008 FY | 262.62 Thousand CAD | -6.12% |
2008 Q3 | 38.92 Thousand CAD | -47.7% |
2008 Q4 | 17.73 Thousand CAD | -54.43% |
2008 Q1 | 131.55 Thousand CAD | 58.15% |
2007 FY | 279.73 Thousand CAD | 7513.91% |
2007 Q1 | 18.29 Thousand CAD | 0.0% |
2007 Q4 | 83.18 Thousand CAD | -13.34% |
2007 Q3 | 95.98 Thousand CAD | 16.68% |
2007 Q2 | 82.26 Thousand CAD | 349.58% |
2006 Q2 | - CAD | 0.0% |
2006 Q3 | - CAD | 0.0% |
2006 Q4 | - CAD | 0.0% |
2006 FY | 3674.00 CAD | 0.0% |
2006 Q1 | - CAD | 0.0% |
2005 FY | - CAD | 0.0% |
Name | Gross Profit | Gross Profit Difference |
---|---|---|
American Bio Medica Corporation | -193 Thousand USD | -136.664% |
Arrayit Corporation | 2.57 Million USD | 117.738% |
Atlantic International Corp. | -154.23 Thousand USD | -196.148% |
Biocept, Inc. | -2.58 Million USD | 82.31% |
Bioqual, Inc. | 7.42 Million USD | 106.148% |
CardioGenics Holdings Inc | - USD | Infinity% |
DermTech, Inc. | 276 Thousand USD | 265.493% |
Global WholeHealth Partners Corporation | - USD | Infinity% |
Hangzhou Tigermed Consulting Co., Ltd. | 6.73 Billion USD | 100.007% |
HTG Molecular Diagnostics, Inc. | 1.79 Million USD | 125.459% |
iMD Companies, Inc. | -23.63 Thousand USD | -1832.398% |
IDenta Corp. | 662.97 Thousand USD | 168.896% |
Interpace Biosciences, Inc. | 23.04 Million USD | 101.982% |
Integrative Health Technologies, Inc. | 77.57 Thousand USD | 688.83% |
InVitro International | 635.98 Thousand USD | 171.819% |
Lumos Diagnostics Holdings Limited | 6.56 Million USD | 106.96% |
Many Bright Ideas Technologies Inc. | - USD | Infinity% |
Medical Imaging Corp. | 1.09 Million USD | 141.802% |
NovelStem International Corp. | 12 Thousand USD | 3906.342% |
Optigenex Inc. | -102.96 Thousand USD | -343.604% |
PharmChem, Inc. | 3.9 Million USD | 111.699% |
Proteome Sciences plc | 2.09 Million USD | 121.785% |
Response Genetics, Inc | 3.94 Million USD | 111.587% |
Rennova Health, Inc. | 6.26 Million USD | 107.287% |
RushNet, Inc. | 1.1 Million USD | 141.35% |
ScreenPro Security Inc. | 856.57 Thousand USD | 153.324% |
Stella Diagnostics Inc. | - USD | Infinity% |
StageZero Life Sciences Ltd. | -403.74 Thousand USD | -13.131% |
Todos Medical Ltd. | 4.31 Million USD | 110.598% |